AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide, offering a diverse portfolio of therapies. The company reported a substantial revenue of $61,160,000,000.00 reflecting its strong market presence. Among its key offerings are HUMIRA, an injection therapy for autoimmune and intestinal Behçet's diseases, and SKYRIZI, which treats moderate to severe plaque psoriasis in adults. Additionally, RINVOQ serves as a JAK inhibitor for moderate to severe active rheumatoid arthritis, while IMBRUVICA and VENCLEXTA are utilized for chronic lymphocytic leukemia and small lymphocytic lymphoma treatment. MAVYRET targets chronic HCV genotype 1-6 infections, and the company also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency. Furthermore, Synthroid is used for hypothyroidism, while Linzess/Constella addresses irritable bowel syndrome with constipation. Lupron targets advanced prostate cancer and other conditions, and Botox therapeutic is part of their offerings. AbbVie continues its innovation with ORILISSA, a treatment for endometriosis pain, and Duopa and Duodopa, which help manage Parkinson's disease. The company’s ophthalmic products include Lumigan/Ganfort for elevated intraocular pressure and Restasis, which boosts tear production. The gross profit ratio is 0.84 reflecting the efficiency of the company's production and sales operations. The earnings per share (EPS) is reported at $2.38 indicating the company's profitability on a per-share basis. Moreover, the net total of other income and expenses is -$14,617,000,000.00 reflecting non-core financial activities, while the weighted average number of shares outstanding is 1,790,678,000.00 highlighting the company's shareholder base. In the financial market, the stock is reasonably priced at $222.47 appealing to a broad range of investors. AbbVie has a high average trading volume of 7,941,300.00 indicating strong liquidity, and boasts a large market capitalization of $370,192,714,910.00 establishing it as a dominant player. It is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape, and belongs to the Healthcare sector, driving innovation and growth. This robust combination of research, product diversity, and solid financial metrics underpins AbbVie's position as a leader in the pharmaceutical market.